Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P27482
UPID:
CALL3_HUMAN
Alternative names:
CaM-like protein; Calmodulin-related protein NB-1
Alternative UPACC:
P27482; B2R9V6; Q5SQI4
Background:
Calmodulin-like protein 3, also known as CaM-like protein or Calmodulin-related protein NB-1, plays a pivotal role in cellular processes. It functions as a specific light chain of unconventional myosin-10 (MYO10), enhancing MYO10 translation. This protein may act as a chaperone for the emerging MYO10 heavy chain protein and competes with calmodulin by binding to cellular substrates with varying affinities.
Therapeutic significance:
Understanding the role of Calmodulin-like protein 3 could open doors to potential therapeutic strategies. Its involvement in the regulation of MYO10 suggests a critical role in cellular mechanics and signaling pathways, offering a novel target for drug discovery.